The rising prevalence of osteoporosis disease further boosting the global postmenopausal osteoporosis market

Published: May 2021

The global postmenopausal osteoporosis market is anticipated to grow at a CAGR of around 3.6% during the forecast period (2021-2027). The key factor that drives the market includes the increasing prevalence of osteoporosis disease among the aged population. For instance, according to International Osteoporosis Foundation, United Nations estimates that the "old age" dependency ratio will be increasing dramatically in the 21st century. By 2030, the ratio is forecasted to be 18 seniors per 100 workers which will be further increased to 25.2 per 100 and 37.6 per 100 by 2050. Almost 9 million fragility fractures are taking place annually that includes 1.6 million hip fractures resulting in premature deaths. 

Browse the full report description of "Global Postmenopausal Osteoporosis Market Size, Share & Trends Analysis Report by Treatment (Bisphosphonates, Hormones, Strontium Ranelate, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/postmenopausal-osteoporosis-market

Rising acquisitions, product approval, product launch collaborations among the major players of the market also propels the growth of the market. For instance, in April 2019, Amgen and UCB announced that the US food and Drug Administration has approved EVENITY for the treatment for postmenopausal osteoporosis in women with a high risk of fractures. EVENITY is one of the first and only bone builder products that have the unique dual effect of increasing bone formation and reducing bone resorption that rapidly reduces the risk of fracture. This approval comes with the post-marketing requirement of the FDA that gives assess of cardiovascular safety of EVENITY in osteoporosis in women with post-menopause. 

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered- 

o By Treatment 

o By Distribution channel 

  • Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

  • Competitive Landscape- Eli Lilly and Co, Pfizer Inc., Proctor & Gamble Co., Amgen Inc., Novartis International AG, Allergan plc.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Postmenopausal Osteoporosis Market Report Segment

By Treatment 

  • Bisphosphonates
  • Hormones
  • Strontium Ranelate
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E- Commerce Pharmacies

Global Postmenopausal Osteoporosis Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-market